ATE512160T1 - T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen - Google Patents

T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen

Info

Publication number
ATE512160T1
ATE512160T1 AT05009095T AT05009095T ATE512160T1 AT E512160 T1 ATE512160 T1 AT E512160T1 AT 05009095 T AT05009095 T AT 05009095T AT 05009095 T AT05009095 T AT 05009095T AT E512160 T1 ATE512160 T1 AT E512160T1
Authority
AT
Austria
Prior art keywords
tumor
present
relates
laminin receptor
immature laminin
Prior art date
Application number
AT05009095T
Other languages
English (en)
Inventor
Matthias Zeis
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of ATE512160T1 publication Critical patent/ATE512160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT05009095T 2005-04-26 2005-04-26 T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen ATE512160T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05009095A EP1717245B1 (de) 2005-04-26 2005-04-26 T-cell-Epitope aus dem unreifen Lamininrezeptorprotein (Oncofoetal Antigen) und deren medizinische Verwendungen

Publications (1)

Publication Number Publication Date
ATE512160T1 true ATE512160T1 (de) 2011-06-15

Family

ID=34935739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05009095T ATE512160T1 (de) 2005-04-26 2005-04-26 T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen

Country Status (14)

Country Link
US (1) US7968097B2 (de)
EP (2) EP1717245B1 (de)
JP (1) JP4870751B2 (de)
CN (1) CN101166759B (de)
AT (1) ATE512160T1 (de)
AU (1) AU2006239505B2 (de)
BR (1) BRPI0610841A2 (de)
CA (1) CA2606088C (de)
EA (1) EA013598B1 (de)
ES (1) ES2367643T3 (de)
NO (1) NO20076041L (de)
NZ (1) NZ563432A (de)
UA (1) UA97092C2 (de)
WO (1) WO2006114307A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2565578T3 (es) * 2002-08-02 2016-04-05 South Alabama Medical Science Foundation Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US7994276B2 (en) * 2007-07-27 2011-08-09 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
DE602008000891D1 (de) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
JP2012522017A (ja) 2009-03-26 2012-09-20 クアンタム イミュノロジクス， インコーポレイテッド 診断適用および臨床適用のための癌胎児抗原／未熟ラミニン受容体抗体
CA2767595A1 (en) * 2009-07-09 2011-01-13 South Alabama Medical Science Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
US20120142109A1 (en) * 2009-08-25 2012-06-07 Yoshinori Katayama Method for producing t cell population under presence of retinoic acid
EP2330122A1 (de) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP-abgeleitetes modifiziertes Peptid
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP4317432A3 (de) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T-zell-rezeptoren mit verbesserter paarung
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CA3059644A1 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2019222760A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center Improved targeted t-cell therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003144A1 (en) 1994-07-27 1996-02-08 The Council Of The Queensland Institute Of Medical Research Polyepitope vaccines
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
ES2565578T3 (es) 2002-08-02 2016-04-05 South Alabama Medical Science Foundation Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20070166318A1 (en) * 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences

Also Published As

Publication number Publication date
EA200702202A1 (ru) 2008-04-28
NO20076041L (no) 2007-11-23
CA2606088A1 (en) 2006-11-02
WO2006114307A1 (en) 2006-11-02
CN101166759A (zh) 2008-04-23
US7968097B2 (en) 2011-06-28
ES2367643T3 (es) 2011-11-07
CA2606088C (en) 2015-05-26
CN101166759B (zh) 2012-09-05
EP1717245A1 (de) 2006-11-02
EA013598B1 (ru) 2010-06-30
EP1874810A1 (de) 2008-01-09
US20090041794A1 (en) 2009-02-12
EP1717245B1 (de) 2011-06-08
NZ563432A (en) 2010-11-26
JP2008538901A (ja) 2008-11-13
BRPI0610841A2 (pt) 2010-07-27
AU2006239505B2 (en) 2012-05-10
UA97092C2 (ru) 2012-01-10
JP4870751B2 (ja) 2012-02-08
AU2006239505A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE512160T1 (de) T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
HK1220709A1 (zh) 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽
EA200800676A1 (ru) Опухолеассоциированные пептиды, связывающиеся с молекулами человеческого лейкоцитарного антигена (hla) i или ii класса, и относящаяся к ним противораковая вакцина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties